Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A

Federico Tacconi1, Giuseppe Mangiameli2,3, Emanuele Voulaz2,3

  • 1Thoracic Surgery and Breast Unit, Department of Surgical Sciences, Tor Vergata University Polyclinic, Viale Oxford 81, 00133 Rome, Italy.

PubMed
Summary

Systemic inflammation markers like NLR, PLR, and SII do not predict lymph node spread in early-stage non-small cell lung cancer (NSCLC). However, elevated platelet-related markers may influence nodal recurrence in larger tumors post-surgery.